Breakthroughs don’t happen in isolation. They happen when researchers, clinicians, patient advocates, pharmaceutical innovators, diagnostics leaders, and nonprofit partners work together with urgency and purpose. Find out how partnering with QLHC’s platform trials and proven site network can accelerate your
research goals. From contract to FPFV in as little as 4 weeks.
From protocol agreement to first participant enrolled — no delays waiting for infrastructure to catch up.
Consistent, high enrollment rates across our national site network, including 18 NCCN member institutions.
Simultaneous testing across multiple tumor biology subtypes provides a comprehensive picture of where your agent works.
Direct, iterative collaboration with the I-SPY network of investigators who shape how new therapies are used, understood, and adopted.
QLHC was built to overcome the challenges holding innovation back. Our platform trials create a shared infrastructure where partners can move faster, learn faster, and bring promising therapies to patients sooner
We actively collaborate with pharmaceutical and diagnostic companies, academic and community institutions, and advocacy groups to evaluate new agents, biomarkers, technologies, and analytical approaches within a proven patient-centered clinical framework
Whether advancing a single therapy or helping shape the future standard of care, our partnerships are designed to create meaningful impact at scale
New clinical trial arms have advanced as quickly as 4 weeks from contract signature to first patient treated — reducing the normal processes from years to weeks
By investigators or your team.
Collaborations team, investigators, and partner work together.
I-SPY Agents Selection Committee reviews new agents proposals monthly.
Once you start, we aim to get protocol and contract done in 4-8 weeks
QLHC executes contract, IRB, and IND amendment.
External expert committee approval conveened just in time.
Regulatory clearance coordinated by QLHC in 4 weeks.
All Sites activated across the national network a month from submission to IRB and FDA.
QLHC leverages advanced data integration, AI-enabled technologies, and secure collaborative systems to help partners generate deeper clinical insights across every stage of research.
We're not looking for a simple yes or no on whether a drug works — we want to understand why, so we can learn how to use it better. Real-time feedback on adverse events helps us manage safety as the trial unfolds, guiding decisions like dose adjustments so each drug gets its best possible shot at success.
Our infrastructure is designed to support platform trials at scale while maintaining the highest standards for data governance, security, compliance, and patient privacy. By connecting data across trials, biomarkers, and patient outcomes, we help accelerate discovery and improve decision-making for sponsors, investigators, and care teams alike.
Co-own your arm data and use it freely for commercialization. Competitor data stays protected — always.
Validate assays and train algorithms on matched specimens and longitudinal data from a uniquely well-characterized population.
De-identified, analysis-ready datasets and biospecimens to power translational science and biomarker programs.
Annotated biospecimens
Longitudinally collected
250K MRI image series across ~15,000 MRI exams in ~3,000 participants
WGS, WES, RNA-Seq
Neutral third-party intermediary
Data oversight and governance committee
Strict data use agreements
De-identified patient data
QLHC collaborates with leading clinical sites nationwide to expand patient access, accelerate enrollment, and advance groundbreaking research through adaptive trials. By joining our network, trial sites gain access to innovative protocols, collaborative scientific leadership, and a proven infrastructure designed to reduce operational friction and accelerate research. Together, we can help bring new innovative treatment options to your patients.
